Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
group A and C meningococcal + Haemophilus influenzae type b conjugate combined vaccine
- Development stage
- Unknown
- Lead developer
- Olymvax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The group A and C meningococcal + Haemophilus influenzae type b conjugate combined vaccine is a trivalent polysaccharide-protein conjugate vaccine developed by Chengdu Olin Biotechnology. It is designed to provide simultaneous protection against invasive diseases caused by *Neisseria meningitidis* serogroups A and C, as well as *Haemophilus influenzae* type b (Hib), in infants and young children. The vaccine utilizes capsular polysaccharides from each pathogen, individually conjugated to a tetanus toxoid carrier protein to enhance immunogenicity, particularly in the pediatric population where pure polysaccharide vaccines are less effective. It has been evaluated in Phase 3 clinical trials (e.g., CTR20191736) comparing its safety and immunogenicity to the separate administration of A+C meningococcal and Hib conjugate vaccines.
- Other names
- Hib-MenAC vaccineA+C meningococcal–Hib conjugate combined vaccinegroup A and C meningococcal–Haemophilus influenzae type b conjugate combined vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)
Beyond the preview
Go deeper on group A and C meningococcal + Haemophilus influenzae type b conjugate combined vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on group A and C meningococcal + Haemophilus influenzae type b conjugate combined vaccine.